Shares of Perrigo Company plc (NYSE:PRGO – Get Free Report) have received an average rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $35.00.
Several research analysts recently issued reports on PRGO shares. Piper Sandler lowered shares of Perrigo from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 target price (down from $50.00) on shares of Perrigo in a report on Monday, September 23rd. StockNews.com downgraded Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, January 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $42.00 target price on shares of Perrigo in a report on Monday, September 30th. Finally, Argus downgraded Perrigo from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th.
Read Our Latest Report on PRGO
Insider Buying and Selling
Hedge Funds Weigh In On Perrigo
Institutional investors and hedge funds have recently modified their holdings of the company. Franklin Resources Inc. purchased a new stake in Perrigo during the third quarter valued at $3,717,000. Barclays PLC increased its position in shares of Perrigo by 44.8% during the 3rd quarter. Barclays PLC now owns 120,502 shares of the company’s stock valued at $3,160,000 after purchasing an additional 37,268 shares during the last quarter. Foundry Partners LLC bought a new position in shares of Perrigo in the 3rd quarter worth approximately $7,111,000. AQR Capital Management LLC boosted its holdings in shares of Perrigo by 675.5% in the second quarter. AQR Capital Management LLC now owns 970,637 shares of the company’s stock worth $24,926,000 after buying an additional 845,470 shares during the last quarter. Finally, Citigroup Inc. grew its position in Perrigo by 94.1% during the third quarter. Citigroup Inc. now owns 151,520 shares of the company’s stock valued at $3,974,000 after buying an additional 73,457 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.
Perrigo Stock Performance
NYSE:PRGO opened at $23.86 on Tuesday. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94. The firm’s fifty day simple moving average is $26.43 and its 200 day simple moving average is $26.72. The stock has a market cap of $3.26 billion, a P/E ratio of -20.40 and a beta of 0.53. Perrigo has a twelve month low of $23.14 and a twelve month high of $33.96.
Perrigo (NYSE:PRGO – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.81. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.12 billion. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business’s revenue was down 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 EPS. As a group, research analysts predict that Perrigo will post 2.56 EPS for the current year.
Perrigo Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 17th. Investors of record on Friday, November 29th were given a dividend of $0.276 per share. The ex-dividend date was Friday, November 29th. This represents a $1.10 annualized dividend and a dividend yield of 4.63%. Perrigo’s dividend payout ratio (DPR) is presently -94.02%.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Further Reading
- Five stocks we like better than Perrigo
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- The Most Important Warren Buffett Stock for Investors: His Own
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- What is the Nasdaq? Complete Overview with History
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.